Overview
Updates in NOAC Reversal, What Have We Learned?
CME Video Commentary
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Dr. Gregory Piazza and Dr. Christian Ruff present recent clinical data, guideline recommendations and updates on navigating the use of newly approved and emerging NOAC reversal agents. This video commentary will include clinical case review and discussions about strategies to navigate the complexities of reversing the anticoagulant effects of NOACs across diverse patient populations in emergent medical situations.
This activity is intended for hospitalists, cardiologists, primary care physicians, nurses
and others with an interest in NOAC reversal.
and others with an interest in NOAC reversal.
The purpose of this activity is to provide clinicians with up to date education on strategies and guideline recommendations for the reversal of anticoagulants including awareness on the efficacy and safety data of newly approved and emerging agents that specifically reverse anticoagulant effects.
After participating in this program, the participant should be able to:
• Review current approaches to the management of bleeding in patients receiving NOACs, as well as unmet needs with current practices
• Compare and contrast approved and emerging reversal agents for NOACs, including their mechanisms of action and available data
• Discuss clinical strategies for NOAC reversal in emergent patient scenarios
• Review current approaches to the management of bleeding in patients receiving NOACs, as well as unmet needs with current practices
• Compare and contrast approved and emerging reversal agents for NOACs, including their mechanisms of action and available data
• Discuss clinical strategies for NOAC reversal in emergent patient scenarios
Sponsored by Academy for Continued Healthcare Learning
Supported by an educational grant from Portola Pharmaceuticals, Inc.
Christian Ruff, MD, MPH
Assistant Professor of Medicine, Harvard Medical School
Associate Physician and Investigator – TIMI Study Group
Cardiovascular Division, Brigham and Women’s Hosptial
Boston, MA
Assistant Professor of Medicine, Harvard Medical School
Associate Physician and Investigator – TIMI Study Group
Cardiovascular Division, Brigham and Women’s Hosptial
Boston, MA
Gregory Piazza, MD, MS
Associate Physician, Brigham and Women’s Hospital
Associate Professor, Harvard Medical School
Boston, MA
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
The following financial relationships have been provided:
Christian Ruff, MD, MPH
Sources of Funding for Research: Boehringer Ingelheim, Daiichi Sankyo, MedImmune, National Institutes of Health
Consulting Agreements/Advisory Boards: Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Janssen, MedImmune, Pfizer, Portola, Anthos
Gregory Piazza, MD, MS
Grants: Bayer, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Portola Pharmaceuticals, Inc.
Advisory Panel: Pfizer
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: NONE
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Provider approved by the California Board of Registered Nursing, Provider Number 17273 for 1 contact hour.
Provider approved by the California Board of Registered Nursing, Provider Number 17273 for 1 contact hour.